Citations

Clear

1526 citation(s) found for "Sun, Yu".

Differential Effects of Extracellular Vesicles of Lineage-Specific Human Pluripotent Stem Cells on the Cellular Behaviors of Isogenic Cortical Spheroids
Marzano, Mark, Bejoy, Julie , Cheerathodi, Mujeeb R., Sun, Li , York, Sara B. , Kanekiyo, Takahisa , Bu, Guojun , Meckes, David G. , Meckes, David G , Bu, Guojun , Zhao, Jing , Li, Yan , Sun, Li

Mayo Clinic

Cells | August 28, 2019 | Volume: 8 | Issue: 9 | Pages: 993

10.3390/cells8090993 | PMID 31466320 Get It

Extracellular vesicles (EVs) contribute to a variety of signaling processes and the overall physiological and pathological states of stem cells and tissues. Human induced pluripotent stem cells (hiPSCs) have unique characteristics that can mimic embryonic tissue development. There is growing interest in the use of EVs derived from hiPSCs as therapeutics, biomarkers, and drug delivery vehicles. However, little is known about the characteristics of EVs secreted by hiPSCs and paracrine signaling during tissue morphogenesis and lineage specification. Methods: In this study, the physical and biological properties of EVs isolated from hiPSC-derived neural progenitors (ectoderm), hiPSC-derived cardiac cells (mesoderm), and the undifferentiated hiPSCs (healthy iPSK3 and Alzheimer’s-associated SY-UBH lines) were analyzed. Results: Nanoparticle tracking analysis and electron microscopy results indicate that hiPSC-derived EVs have an average size of 100–250 nm. Immunoblot analyses confirmed the enrichment of exosomal markers Alix, CD63, TSG101, and Hsc70 in the purified EV preparations. MicroRNAs including miR-133, miR-155, miR-221, and miR-34a were differently expressed in the EVs isolated from distinct hiPSC lineages. Treatment of cortical spheroids with hiPSC-EVs in vitro resulted in enhanced cell proliferation (indicated by BrdU+ cells) and axonal growth (indicated by β-tubulin III staining). Furthermore, hiPSC-derived EVs exhibited neural protective abilities in Aβ42 oligomer-treated cultures, enhancing cell viability and reducing oxidative stress. Our results demonstrate that the paracrine signaling provided by tissue context-dependent EVs derived from hiPSCs elicit distinct responses to impact the physiological state of cortical spheroids. Overall, this study advances our understanding of cell‒cell communication in the stem cell microenvironment and provides possible therapeutic options for treating neural degeneration.
Abstract 681: Methylation biomarkers of cellular response to demethylating drug
Kocher, Jean‐Pierre , Sun, Zhifu, Wang, Xuewei

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 681-681

10.1158/1538-7445.am2019-681 Get It

Abstract DNA methylation plays an import role in both tumorigenesis and therapy resistance. Demethylating drug regimens have shown efficacy in hematological malignancies, and are actively studied for other cancer types. High variability in patients’ responses to these drugs has been observed and highlights the demand to identify predictive biomarkers for these demethylating drugs. In particular, decitabine (latest FDA-approved demethylating drug) demonstrated as the most potent agent and has the best response on hematological cell lines. Two public datasets were collected to identify methylation biomarkers of decitabine. The first one is from Genomics of Drug Sensitivity in Cancer, with methylation data from Illumina 450K array and drug response from cell lines. The other one is a publicly available patient dataset (methylations from RRBS sequencing and decitabine response from clinic). 64900 CpG sites common to the two methylation platforms were used to train machine learning model (Elastic Net), based on the methylation data and decitabine response (AUC) from 108 hematological cell lines in GDSC. 73 CpGs were identified as predictive biomarkers by Elastic Net. The trained model was then used to make predictions on 39 patients (20 responders and 19 non-responders) with their methylation profiles of the same set of CpGs. The predicted response of responder group is indeed better than non-responder group (p-value = 0.0501), indicating the validity of identified methylation biomarkers. The top one CpG identified by Elastic Net resides in the promoter region of gene C20orf85, and is significantly hypermethylated in non-responder group (p-value = 0.0458), suggesting its potential involvement in the resistance to decitabine. Citation Format: Xuewei Wang, Jean-Pierre Kocher, Zhifu Sun. Methylation biomarkers of cellular response to demethylating drug [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 681.
Abstract 4176: Familial lung cancer exhibits multiple novel linked haplotypes within pedigrees
Sun, Haiming , Moiz, Bilal A., Pikielny, Claudio W. , Mandal, Diptasri , Gaba, Colette , Yang, Ping , Li, Yafang , You, Ming , Wilson, Richard K., Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Musolf, Anthony M. , Sun, Haiming, Andrade, Mariza de , Pinney, Susan M. , Amos, Christopher I. , Govindan, Ramaswamy , Bailey‐Wilson, Joan E.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 4176-4176

10.1158/1538-7445.am2019-4176 Get It

Abstract Lung cancer (LC) kills more people in the United States each year than any other cancer. While it is well known that a variety of environmental factors (particularly tobacco smoke) strongly increase the risk of LC, there are multiple associated genetic variants with small contributions to risk. High aggregation of LC within rare individual families suggest that there are high-risk genetic variants as well. However, these genetic risk factors for LC are under studied due to the rapid fatality of LC. We studied 28 highly aggregated extended high-risk familial lung cancer (HRFLC) families collected from eight different sites across the US. Whole exome sequencing was performed on 290 individuals from these families to identify potential risk variants for HRFLC using genetic linkage analysis. Quality control was performed on the sequence data, filtering on parameters such as read depth, genotype quality, missingness, and Mendelian inconsistencies. Identity-by-descent (IBD) values were also calculated to verify correct familial relationships. Quality control procedures left approximately 400,000 SNVs and indels for analysis.Parametric two-point linkage analysis was performed assuming an autosomal dominant mode of inheritance. Disease allele frequency was set to 1% with a penetrance of 80% for carriers and 1% phenocopy rate. While we did not identify any genome-wide significant variants across the 28 families, multiple suggestive variants were identified. The largest cluster of suggestive variants was located at 14q32 in the CATSPERB gene. Given the likely locus heterogeneity in LC (combined with the lack of power in some families), it is not surprising that none of the variants were significant across the families; looking at the individual family results proved more informative. Long haplotypes linked to LC risk were identified in multiple families. These long runs of positive linkages, which have little to no negative linkage evidence across them, are characteristic of true linkage signals in these types of analysis. Two of the most interesting linked regions were at 7p36.1 and 4q21.23-28.23. The 7p signal (observed in a single family) was genome-wide suggestive and located within the SSPO gene. SSPO has been implicated in breast and skin cancer (melanoma); it is a novel lung cancer signal. The 4q linkage (again observed in a single family) covers a large chunk of 4q and contains multiple potential candidate genes, however, the best candidate gene is PTPN13, a gene implicated in lung cancer but never in familial lung cancer. We are currently evaluating the individual family results of several other pedigrees and plan to perform additional analyses to confirm these linkages. Citation Format: Anthony Musolf, Haiming Sun, Bilal A. Moiz, Claudio W. Pikielny, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, Yafang Li, Ming You, Richard K. Wilson, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos, Ramaswamy Govindan, Joan E. Bailey-Wilson. Familial lung cancer exhibits multiple novel linked haplotypes within pedigrees [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4176.
Abstract 3171: Delta-like protein 3 expression in Merkel cell carcinoma
Isse, Kumiko, Ramoth, Johanna, French, Dorothy, Saunders, Laura R. , Xie, Hao , Sun, Yan , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 3171-3171

10.1158/1538-7445.am2019-3171 Get It

Abstract Purpose: Delta-like protein 3 (DLL3) is being developed as a predictive biomarker to identify small cell lung cancer (SCLC) patients for treatment with the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine (Rova-T). Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin, associated with Merkel cell polyomavirus. Given the neuroendocrine features of SCLC and MCC, we sought to evaluate DLL3 expression, its association with common clinicopathological factors, and its prognostic role in MCC. Methods: A total of 65 formalin-fixed and paraffin-embedded MCC cases were consecutively identified from an institutional biospecimen repository and were cut at 5 µm. Each case was stained for DLL3 protein with SC16.65 mouse monoclonal antibody at 3 µg/mL with the FLEX+ system (DAKO). Slides were then scanned at 20X with AT2 (Leica/Aperio) and read out for percentage of positive tumor cells with 1+, 2+, and 3+ intensity side-by-side with isotype control (IgG2a). Any subcellular staining pattern (membranous, cytoplasmic or punctate) was counted as overall positive. Polyomavirus status was determined by immunohistochemistry (IHC) using an antibody that binds to MCPyV large T-antigen (sc-136172, Santa Cruz Biotechnology, Inc.). A generalized additive model was used to visualize the trend between common clinical factors and overall survival (OS). A multivariable Cox proportional hazards model was applied to assess the association between DLL3 expression and OS. The association between DLL3 expression and other clinicopathological factors was evaluated with median and t tests. Results: A total of 67 patients were included with a median age of 74 years. Thirty-six (55%) had stage I/II disease; 29 (45%) had stage III/IV disease. Thirty-five (52%) patients died from MCC. Among the 65 cases with successful DLL3 stain, the median H-score of DLL3 expression was 60 (interquartile range: 30-100). Fifty-eight cases (89%) had ≥1% tumor cells positive for DLL3 expression with any intensity, of which the median DLL3 expression was 50% (interquartile range: 25-70%). Thirty-four cases (52%) had ≥50% tumor cells positive for DLL3 expression with any intensity. Older age significantly predicted shorter overall survival (p = 0.03). However, higher AJCC stage did not predict shorter OS (p = 0.3). H-score of DLL3 expression was not associated with AJCC stages (p = 0.4). However, higher H-score of DLL3 expression was associated with higher polyomavirus nuclear expression (p = 0.02) when it was dichotomized to 0/1+ and 2+/3+. In a multivariable Cox regression analysis, H-score of DLL3 expression did not predict OS of patients with MCC (p = 0.8). Conclusions: DLL3 overexpression is very common in MCC by IHC. DLL3 expression was significantly associated with Merkel cell polyomavirus expression but was not prognostic for OS in this cohort. The high levels of DLL3 expression in a subset of MCC may potentially be used to select patients to receive Rova-T. Citation Format: Hao Xie, Kumiko Isse, Yan Sun, Johanna Ramoth, Dorothy M. French, Laura R. Saunders, Aaron S. Mansfield. Delta-like protein 3 expression in Merkel cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3171.
Emergency response to radiological and nuclear accidents and incidents
Gale, Robert Peter , Hashmi, Shahrukh K. , Gale, Robert P , Armitage, Jamés O.

Mayo Clinic

British Journal of Haematology | August 7, 2019 | Volume: 192 | Issue: 6 | Pages: 968-972

10.1111/bjh.16138 | PMID 31388987 Get It

SummaryBone marrow damage is an important consequence of exposure to acute high‐dose whole‐body radiation. As such, haematologists can play an important role in managing this complication. However, these accident and incident scenarios are complex and often involve injuries to other organs and tissues from heat, projectiles and chemicals. In the case of a large‐scale event there will likely be severe infrastructure disruptions and injury or death to medical personnel. Accurate estimates of dose and uniformity of exposure are needed to intelligently direct appropriate interventions, which range from antibiotics, antifungals and anti‐virus drugs, molecularly‐cloned haematopoietic growth factors and, in rare instances, haematopoietic cell transplants. These therapies are ones that haematologists often use in the context of anti‐cancer therapy, especially therapy of haematological cancers like leukaemia. However, most haematologists have little knowledge of radiation biology and should consider updating this aspect of their expertise in continuing medical education. As in other areas of medicine, prevention is better than cure and haematologists should be active in decreasing risks of a nuclear war.
Trends in Direct Hospital Payments to Anesthesia Groups
O’Connell, Chloe, Dexter, Franklin , Mauler, David J. , Sun, Eric

Mayo Clinic

Anesthesiology | July 8, 2019 | Volume: 131 | Issue: 3 | Pages: 534-542

10.1097/aln.0000000000002819 | PMID 31283739 Get It

Abstract Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New Background In addition to payments for services, anesthesia groups in the United States often receive revenue from direct hospital payments. Understanding the magnitude of these payments and their association with the hospitals’ payer mixes has important policy implications. Methods Using a dataset of financial reports from 240 nonacademic California hospitals between 2002 and 2014, the authors characterized the prevalence and magnitude of direct hospital payments to anesthesia groups, and analyzed the association between these payments and the fraction of anesthesia revenue derived from public payers ( e.g. , Medicaid). Results Of hospitals analyzed, 69% (124 of 180) made direct payments to an anesthesia group in 2014, compared to 52% (76 of 147) in 2002; the median payment increased from $242,351 (mean, $578,322; interquartile range, $72,753 to $523,861; all dollar values in 2018 U.S. dollars) to $765,128 (mean, $1,295,369; interquartile range, $267,006 to $1,503,163) during this time period. After adjusting for relevant covariates, hospitals where public insurers accounted for a larger fraction of anesthesia revenues were more likely to make direct payments to anesthesia groups (β = 0.45; 95% CI, 0.10 to 0.81; P = 0.013), so that a 10–percentage point increase in the fraction of anesthesia revenue derived from public payers would be associated with a 4.5–percentage point increase in the probability of receiving any payment. Among hospitals making payments, our results (β = 2.10; 95% CI, 0.74 to 3.45; P = 0.003) suggest that a 1–percentage point increase in the fraction of anesthesia revenue derived from public payers would be associated with a 2% relative increase in the amount paid. Conclusions Direct payments from hospitals are becoming a larger financial consideration for anesthesia groups in California serving nonacademic hospitals, and are larger for groups working at hospitals serving publicly insured patients.
Association Between Participation and Performance in MOCA Minute and Actions Against the Medical Licenses of Anesthesiologists
Zhou, Yan , Macario, Alex, Keegan, Mark T. , Minhaj, Mohammed , Wang, Ting , Harman, Ann E., Sun, Huaping, Patterson, Andrew J., Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | July 8, 2019 | Volume: 129 | Issue: 5 | Pages: 1401-1407

10.1213/ane.0000000000004268 | PMID 31274598 Get It

BACKGROUND: In January 2016, as part of the Maintenance of Certification in Anesthesiology (MOCA) program, the American Board of Anesthesiology launched MOCA Minute, a web-based longitudinal assessment, to supplant the former cognitive examination. We investigated the association between participation and performance in MOCA Minute and disciplinary actions against medical licenses of anesthesiologists. METHODS: All anesthesiologists with time-limited certificates (ie, certified in 2000 or after) who were required to register for MOCA Minute in 2016 were followed up through December 31, 2016. The incidence of postcertification prejudicial license actions was compared between those who did and did not register and compared between registrants who did and did not meet the MOCA Minute performance standard. RESULTS: The cumulative incidence of license actions was 1.2% (245/20,006) in anesthesiologists required to register for MOCA Minute. Nonregistration was associated with a higher incidence of license actions (hazard ratio, 2.93 [95% confidence interval {CI}, 2.15–4.00]). For the 18,534 (92.6%) who registered, later registration (after June 30, 2016) was associated with a higher incidence of license actions. In 2016, 16,308 (88.0%) anesthesiologists met the MOCA Minute performance standard. Of those not meeting the standard (n = 2226), most (n = 2093, 94.0%) failed because they did not complete the required 120 questions. Not meeting the standard was associated with a higher incidence of license actions (hazard ratio, 1.92 [95% CI, 1.36–2.72]). CONCLUSIONS: Both timely participation and meeting performance standard in MOCA Minute are associated with a lower likelihood of being disciplined by a state medical board.
Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson’s Disease
Driver‐Dunckley, Erika , Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Davis, Kathryn, Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Parkinson’s Disease | July 5, 2019 | Volume: 9 | Issue: 3 | Pages: 543-552

10.3233/jpd-191610 | PMID 31282425 Get It

Background: Some epidemiology studies suggest that atherosclerotic cardiovascular disease (ASCVD) risk factors increase the risk of developing Parkinson’s disease (PD). However, conflicting data suggest lower rates of ASCVD in PD. Objective: The objective of this study is to determine, with data from a longitudinal clinicopathological study, whether ASCVD risk factors are associated with a PD diagnosis and/or increased brain or peripheral load of Lewy-type synucleinopathy (LTS). Methods: All subjects were followed to autopsy and neuropathological examination in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Multivariable regression models, including age, gender, and smoking history, were used to investigate the association of a PD diagnosis or brain or submandibular gland LTS load with ASCVD risk factors. Results: 150 subjects were included (PD n = 60, controls n = 90). Univariable comparisons and regression models showed a general trend to inverse associations. The multivariable odds ratio (OR) of brain LTS load for carotid artery disease was 0.93 (95% CI: 0.86 to 0.98; p = 0.02), for anticoagulant use 0.95 (95% CI: 0.90 to 0.99; p = 0.04) and for abnormal heart weight 0.96 (95% CI: 0.92 to 0.99; p = 0.01). Composite clinical and overall (clinical + pathology composite risk scores) composite risk scores were also significantly lower in the PD subjects ( p = 0.0164 and 0.0187, respectively). Submandibular gland LTS load was not significantly related to ASCVD conditions. Conclusions: This study shows associations of higher brain LTS with lower prevalence of both clinical and pathological indices of ASCVD in PD subjects versus age-similar controls. We suggest that this is due to α-synuclein pathology-induced sympathetic denervation in PD.
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway
Kothari, Vishal , Goodwin, Jonathan F., Zhao, Shuang G. , Chang, S. Laura , Evans, Joseph R. , Wilder-Romans, Kari , Gabbara, Kristina M., Dylgjeri, Emanuela , Sun, Grace Y., Tomlins, Scott A. , Mehra, Rohit , Hege, Kristen , Filvaroff, Ellen, Schaeffer, Edward M. , Karnes, R. Jeffrey , Quigley, David A. , Speers, Corey , Spratt, Daniel E. , Gilbert, Luke A. , Ashworth, Alan , Chinnaiyan, Arul M., Raj, Ganesh V. , Feng, Felix Y. , Speers, Corey , Spratt, Daniel E , Zhao, Shuang G , Drake, Justin M , Yin, Yi Ming , Chou, Jonathan , Rathkopf, Dana E , He, Housheng Hansen , Knudsen, Karen E.

Mayo Clinic

Clinical Cancer Research | July 2, 2019 | Volume: 25 | Issue: 18 | Pages: 5608-5622

10.1158/1078-0432.ccr-18-2387 | PMID 31266829 Get It

Abstract Purpose: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo. Results: DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription. Conclusions: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Ahn, Kwang Woo , Hu, Zhen‐Huan , Volpe, Virginia O. , Antin, Joseph H. , Sorror, Mohamed L. , Press, Oliver W. , Pidala, Joseph, Negrin, Robert S., Uberti, Joseph P., Agura, Edward, Nash, Richard A. , Mehta, Jayesh, Forman, Stephen J. , Langston, Amelia , Hale, Gregory A., Marks, David I. , Ganguly, Sid, Reshef, Ran , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Cahn, Jean‐Yves, Solh, Melhem , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Aljurf, Mahmoud , Schouten, Harry C. , Hill, Brian T. , Pawarode, Attaphol , Kindwall‐Keller, Tamila L. , Saba, Nakhle S. , Copelan, Edward A. , Nathan, Sunita , Beitinjaneh, Amer , Černý, Jan , Wirk, Baldeep , Olsson, Richard F. , Bashey, Asad, Sobecks, Ronald , Alyea, Edwin P. , Saber, Wael , Brown, Jennifer R. , Hogan, William, Kharfan-Dabaja, Mohamed A., Saad, Ayman , Press, Oliver , Olsson, Richard F , Reshef, Ran , Kim, Haesook T. , Davids, Matthew S. , Shadman, Mazyar , Hogan, William J. , Devine, Steven M. , McGuirk, Joseph P. , Giralt, Sergio , Perales, Miguel‐Angel , Battiwalla, Minoo , Gale, Robert Peter , Hamadani, Mehdi , Bacher, Ulrike , Lazarus, Hillard M. , Cahn, Jean‐Yves , Ghosh, Nilanjan , Savani, Bipin N. , Grunwald, Michael R. , Yared, Jean A. , Nishihori, Taiga , Chhabra, Saurabh , Gergis, Usama , Popat, Uday R , Sorror, Mohamed

Mayo Clinic

Clinical Cancer Research | June 28, 2019 | Volume: 25 | Issue: 16 | Pages: 5143-5155

10.1158/1078-0432.ccr-18-3988 | PMID 31253630 Get It

Abstract Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P < 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P < 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or ≥5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P < 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.